Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 24:10:902.
doi: 10.3389/fimmu.2019.00902. eCollection 2019.

Dynamics of the Type I Interferon Response During Immunosuppressive Therapy in Rheumatoid Arthritis

Tamarah D de Jong  1 , Tanja Snoek  1 , Elise Mantel  1 , Conny J van der Laken  1 , Ronald F van Vollenhoven  1 , Willem F Lems  1
Affiliations

Dynamics of the Type I Interferon Response During Immunosuppressive Therapy in Rheumatoid Arthritis

Tamarah D de Jong et al. Front Immunol. .

Abstract

Objective: The type I interferon (IFN) response in rheumatoid arthritis (RA) has been extensively studied in relation to therapy with biological DMARDs (bDMARDs). However, the effect of conventional synthetic (cs)DMARDs and glucocorticoids (GCs) on IFN response gene (IRG) expression remains largely unknown, even though csDMARDS are used throughout all disease phases, including simultaneously with biologic therapy. This study was aimed to determine the dynamics of IFN response upon immunosuppressive treatment. Methods: Whole blood was collected in PAXgene tubes from 35 RA patients who received either COBRA therapy (combination of prednisone, initially 60 mg, methotrexate and sulfasalazine) (n = 14) or COBRA-light therapy (prednisone, initially 30 mg, and methotrexate) (n = 21). Expression of 10 IRGs was determined by real-time PCR at baseline (T0), after 4 weeks (T4), and 13 weeks (T13) of treatment. IRG selection was based on the differential presence of transcription factor binding sites (TFBS), in order to study the therapy effect on different pathway components involved in IFN signaling. Results: Seven of the 10 IRGs displayed significant changes during treatment (p ≤ 0.016). These 7 IRGs all displayed a particularly pronounced decrease between T0 and T4 (≥1.6-fold, p ≤ 0.0059). The differences between IRG sensitivity to the treatment appeared related to the presence of TFBS for STAT1 and IRF proteins within the genes. The extent of the decreases between T0 and T4 was similar for the COBRA- and COBRA-light-treated group, despite the differences in drug combination and doses in those groups. Between T4 and T13, however, IRG expression in the COBRA-light-treated group displayed a significant increase, whereas it remained stable or decreased even further in most COBRA-treated patients (comparison of mean fold changes, p = 0.011). A significant association between IRG dynamics and clinical response to therapy was not detected. Conclusions: Immunosuppressive treatment with csDMARDs, in this case a combination of prednisolone, methotrexate and sulfasalazine, substantially downregulates the IFN response in RA patients. The dynamics of this downregulation were partly dependent on the presence of TFBS within the IRGs and the combination and dosages of agents, but they were irrespective of the clinical response to therapy.

Keywords: biomarker; immunosuppression; interferon; interferon response; rheumatoid arthritis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression dynamics of individual IRGs during COBRA and COBRA-light therapy. Both cohorts were merged for initial analysis.
Figure 2
Figure 2
Expression dynamics of individual IRGs during COBRA and COBRA-light therapy. IRGs were categorized based on the presence or absence of transcription factor binding sites (TFBS) for IRF proteins and/or STAT1. FC, fold change expressed in 2log values. P-values are indicated for longitudinal analysis by Friedman test.
Figure 3
Figure 3
Comparison of longitudinal changes in 7-IRG score between COBRA (C) and COBRA-light(CL)-treated RA patients. *p < 0.05.
See this image and copyright information in PMC

References

    1. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. . Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med. (2001) 111:446–51. 10.1016/S0002-9343(01)00872-5 - DOI - PubMed
    1. van Aken J, Lard LR, le Cessie S, Hazes JM, Breedveld FC, Huizinga TW. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis. (2004) 63:274–9. 10.1136/ard.2003.010298 - DOI - PMC - PubMed
    1. den Uyl D, ter Wee M, Boers M, Kerstens P, Voskuyl A, Nurmohamed M, et al. . A non-inferiority trial of an attenuated combination strategy (‘COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis. (2014) 73:1071–8. 10.1136/annrheumdis-2012-202818 - DOI - PMC - PubMed
    1. ter Wee MM, den Uyl D, Boers M, Kerstens P, Nurmohamed M, van Schaardenburg D, et al. . Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum Dis. (2015) 74:1233–40. 10.1136/annrheumdis-2013-205143 - DOI - PubMed
    1. Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, van der Wijden LKM, et al. . Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. Rheumatology. (2017) 56:1586–96. 10.1093/rheumatology/kex223 - DOI - PubMed

Publication types

MeSH terms